6533b7cffe1ef96bd12597d8

RESEARCH PRODUCT

Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.

Theresa Margaret GoldOguz AkinSujata PatilJane HouldsworthBanumathy GowrishankarAndreas HoetkerAna M. MolinaChung-han LeeRobert J. MotzerManickam Janakiraman

subject

OncologyCancer Researchmedicine.medical_specialtySunitinibbusiness.industryDiseaseurologic and male genital diseasesmedicine.diseaseClear cell renal cell carcinomaOncologyRenal cell carcinomaInternal medicinemedicineIn patientbusinessmedicine.drug

description

e16109Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease with progression as the best response. This s...

https://doi.org/10.1200/jco.2016.34.15_suppl.e16109